Jullian N.
- Country
- Belgium
- Department
- Radiotherapy-Oncology
Research Overview
- Metastasis-directed therapy in oligoprogressive castration-refractory prostate cancer: a randomized phase 3 trial
- Metastasis-directed therapy for oligorecurrent prostate cancer : A randomized phase III trial.
- Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial
Data & Insights
Has run more than one trial at 9 of 25 partner sites.
Specializations
Prostate Cancer Management
This investigator specializes in the treatment of oligorecurrent hormone-sensitive prostate cancer and high-risk prostate cancer, with particular emphasis on innovative therapeutic approaches.
- Metastasis-directed therapy (MDT)
- Hormone therapy optimization
- Advanced diagnostic imaging
Their research interests encompass the integration of targeted therapies with hormone treatment modalities.
Advanced Imaging Applications
The investigator focuses on implementing novel diagnostic radio- and molecular tracers in prostate cancer treatment, particularly utilizing PSMA PET/CT imaging for disease monitoring.
- Molecular imaging techniques
- Treatment response assessment
- Disease progression monitoring
Their work involves the application of advanced imaging for precise treatment guidance and outcome evaluation.
Therapeutic Innovation
The investigator explores combination therapy approaches including the integration of androgen receptor targeted therapy with conventional treatments.
- Quality of life assessment
- Treatment intensification strategies
- Novel therapeutic combinations
Their research encompasses both intensification and de-intensification treatment strategies in prostate cancer management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.